Press Release Archive

12.01.2025

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder Cancer

12.01.2025

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

11.21.2025

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

11.13.2025

Pfizer Completes Acquisition of Metsera

11.12.2025

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.05.2025

Pfizer Responds to Delaware Chancery Court Ruling

11.04.2025

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

11.03.2025

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk

10.31.2025

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

10.31.2025

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

10.30.2025

Pfizer Addresses Proposal for Metsera

10.19.2025

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer